This study, led by Sandra Casimiro and Luis Costa from the Oncology Translational Lab at GIMM CARE, part of the GIMM Foundation – Gulbenkian Institute for Molecular Medicine, demonstrates the potential efficacy of a novel therapeutic strategy for triple-negative breast cancer (TNBC) — an aggressive form of breast cancer for which treatment options are largely limited to chemotherapy.
